scholarly journals STEP TOWARDS UNDERSTANDING THE MYSTERY OF MENIERE’S DISEASE THROUGH AYURVEDA

2021 ◽  
Vol p5 (02) ◽  
pp. 2740-2745
Author(s):  
Anuradha Biserotti ◽  
Prashanth A. S

Meniere’s disease is an inner ear disease characterised by episodes of Vertigo, fluctuating sensorineural hearing loss and Tinnitus, associated with Aural pressure Drop attacks (falls without loss of consciousness), Nystagmus, Headache and Nausea. Relapsing nature of the disease hampers the quality of life in patients. And also affects the psychosocial status of the patient. The main pathology occurs as the result of endo-lymphatic system distension, caused by the excessive accumulation of endolymph. This can result from excessive production or reduced absorption of endolymph or both. By knowing the pathology of the Meniere’s disease, clinical features and signs we can consider Karna Nada, Karna Kshweda, (Tinnitus) Badhirya (Hearing Loss) and Bhrama (vertigo) into consideration in which we encounter the vitiation of Karnagata Tarpaka Kapha and Vata. Hence treatment should be aimed at Agni deepana, Vata Anulomana, Vata Kapha Shamana. Nasya Karma, Karna Poorana, Shamana Snehapana, Snigdha Virechana can be employed in the management of Meniere’s Disease.

2021 ◽  
Vol 9 (2) ◽  
pp. 473-478
Author(s):  
Anuradha Biserotti ◽  
Prashanth A. S

Meniere’s disease is an inner ear disease characterised by episodes of Vertigo, fluctuating sensorineural hearing loss and Tinnitus, associated with Aural pressure Drop attacks (falls without loss of consciousness), Nystagmus, Headache and Nausea. Relapsing nature of the disease hampers the quality of life in patients. And also affects the psychosocial status of the patient. The main pathology occurs as the result of endo-lymphatic system distension, caused by the excessive accumulation of endolymph. This can result from excessive production or reduced absorption of endolymph or both. By knowing the pathology of the Meniere’s disease, clinical features and signs we can consider Karna Nada, Karna Kshweda, (Tinnitus) Badhirya (Hearing Loss) and Bhrama (vertigo) into consideration in which we encounter the vitiation of Karnagata Tarpaka Kapha and Vata. Hence treatment should be aimed at Agni deepana, Vata Anulomana, Vata Kapha Shamana. Nasya Karma, Karna Poorana, Shamana Snehapana, Snigdha Virechana can be employed in the management of Meniere’s Disease.


2019 ◽  
Vol 160 (4) ◽  
pp. 144-150 ◽  
Author(s):  
András Molnár ◽  
Maihoub Stefani ◽  
László Tamás ◽  
Ágnes Szirmai

Abstract: Introduction: Ménière’s disease is a disorder of the inner ear, characterized by episodic rotational vertigo, sensorineural hearing loss, tinnitus, aural pressure and vegetative symptoms. Since the improvement of these symptoms exerts an influence on the patients’ quality of life and the condition seems to be incurable, the symptomatic treatment suggests an important question. Aim: Our study’s aim is to evaluate how hypertension and diabetes exert influence on the patients’ quality of life and how effective conservative pharmacologic treatment is. According to our assumption, both comorbidities have a significant influence on the symptoms and the therapy. Material and method: Complete hospital documentation of 105 (31 men and 74 women, mean ± SD age, 57.4 ± 11.05) patients with definite Ménière’s disease was analysed. The performance of the statistical analysis was completed by using IBM’s SPSS V24 software. Results: The appearance of comorbid patients was more frequent than that of not comorbid patients. The influence of hypertension was supported by the tendency of the vertigo attacks, the higher doses of betahistine, and the larger need for the course of infusions. In the case of hearing loss, the negative effects of diabetes were confirmed by the more frequent appearance of the higher stages of hearing loss and the incidence of the hearing loss’ damage, whereas in the relationship between the hearing loss and hypertension by the negative reply to the conservative therapy. Conclusion: The comorbidities have considerable effect on the condition of MD patients, so internal medical control is essential because of the control of the quality of life. Orv Hetil. 2019; 160(4): 144–150.


2021 ◽  
pp. 1-33
Author(s):  
Babette Van Esch ◽  
Hester van der Zaag-Loonen ◽  
Tjasse Bruintjes ◽  
Peter Paul van Benthem

<b><i>Background:</i></b> Ménière’s disease is characterized by recurrent episodes of vertigo, hearing loss, and tinnitus, often with a feeling of fullness in the ear. Although betahistine is thought to be specifically effective for Ménière’s disease, no evidence for a benefit from the use of betahistine exists, despite its widespread use. Reassessment of the effect of betahistine for Ménière’s disease is now warranted. <b><i>Search Methods:</i></b> We searched for randomized controlled trials (RCTs) in the Central Register of Controlled Trials (CENTRAL), Ovid Medline, Ovid Embase, CINAHL, Web of Science, Clinicaltrials.gov, ICTRP, and additional sources for published and unpublished trials, in which betahistine was compared to placebo. <b><i>Data Collection and Analysis:</i></b> Our outcomes involved vertigo, significant adverse effect (upper gastrointestinal discomfort), hearing loss, tinnitus, aural fullness, other adverse effects, and disease-specific health-related quality of life. We used GRADE to assess the quality of the evidence. <b><i>Main Results:</i></b> We included 10 studies: 5 studies used a crossover design and the remaining 5 were parallel-group RCTs. One study with a low risk of bias found no significant difference between the betahistine groups and placebo with respect to vertigo after a long-term follow-up period. No significant difference in the incidence of upper gastrointestinal discomfort was found in 2 studies (low-certainty evidence). No differences in hearing loss, tinnitus, or well-being and disease-specific health-related quality of life were found (low- to very low-certainty of evidence). Data on aural fullness could not be extracted. No significant difference between the betahistine and the placebo groups (low-certainty evidence) could be demonstrated in the other adverse effect outcome with respect to dull headache. The pooled risk ratio for other adverse effect in the long term demonstrated a lower risk in favor of placebo over betahistine. <b><i>Conclusions:</i></b> High-quality studies evaluating the effect of betahistine on patients with Ménière’s disease are lacking. However, one study with low risk of bias found no evidence of a difference in the effect of betahistine on the primary outcome, vertigo, in patients with Ménière’s disease when compared to placebo. The main focus of future research should be on the use of comparable outcome measures by means of patient-reported outcome measures.


2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Augusto Pietro Casani ◽  
Elena Navari ◽  
Giorgio Guidetti ◽  
Michel Lacour

Menière’s disease is a disorder of the inner ear that causes vertigo, tinnitus, fullness, and hearing loss. Several pharmacological treatments are available, but none of them has shown significant results. Betahistine has been largely used but its effect on the main symptoms of Menière’s disease remains unclear. In order to improve clinical appropriateness and to reduce the heterogeneity of the therapeutic approaches for Menière’s disease, we proposed a European Consensus Conference on Betahistine’s prescription. A group of European experts in vestibular disorders completed a questionnaire, prepared by opinion leaders, on the use of betahistine in Menière’s disease. The Delphi method was used as an iterative investigation method in order to increase and establish the consensus. While betahistine was considered useful to reduce the number of the vertigo attacks during the intercritical phase of the disease, its use during attacks was considered helpful only when associated with other drugs. Betahistine was not considered useful for preventing hearing loss. The experts support the use of betahistine during the intercritical phase of the disease to reduce the number and severity of vertigo episodes. They also defined the parameters for a good clinical approach to evaluate the efficacy of betahistine treatment for Menière’s disease.


2018 ◽  
Vol 160 (2) ◽  
pp. 232-238 ◽  
Author(s):  
Daniel P. Ballard ◽  
Daniel C. Sukato ◽  
Alisa Timashpolsky ◽  
Seilesh C. Babu ◽  
Richard M. Rosenfeld ◽  
...  

Objective Several surgical interventions are offered to patients with Ménière’s disease (MD) who fail medical management. Although outcomes have historically been reported according to American Academy of Otolaryngology—Head and Neck Surgery guidelines, patient-reported outcome measures (PROMs) are increasingly used to evaluate treatments. This study reviews PROMs used to assess surgical treatments for MD and compares the effect of each intervention based on PROM scores. Data Sources PubMed, EMBASE, CINAHL, and Web of Science. Review Methods This is a systematic review and meta-analysis of English-language studies that reported PROMs for surgical treatments of MD. Two independent investigators assessed study eligibility, rated the quality using Methodological Index for Non-Randomized Studies (MINORS), and abstracted data for comparative analysis. A random-effects model was used for meta-analysis of pooled data. Results Of 148 unique studies identified, 11 satisfied inclusion criteria. The Ménière’s Disease Outcome Questionnaire (MDOQ) was the most commonly used survey. Interventions included intratympanic gentamicin, vestibular nerve section, endolymphatic sac surgery, and labyrinthectomy. Pooled analysis of 8 studies that used the MDOQ instrument demonstrated statistically significant improvements in quality of life but did not identify a difference between destructive and nondestructive procedures. Conclusion Although our review shows significant improvements in PROM scores for both destructive and nondestructive interventions, there was no significant difference noted between treatment types. We cannot draw conclusions regarding the comparative effectiveness of specific interventions, and the results do not account for placebo effects or the natural history of the disease. Further investigation with randomized controlled trials should be considered in future studies.


1981 ◽  
Vol 19 (5) ◽  
pp. 17-18

Vertigo and dizziness are major symptoms of disturbed vestibular function. Sudden attacks of vertigo, associated with tinnitus and sensorineural hearing loss, occur in a wide variety of disorders of the inner ear, and when no underlying cause can be found the condition is termed ménière’s disease.


Sign in / Sign up

Export Citation Format

Share Document